CD19 has been extensively studied as a promising therapeutic target for CAR-based immunotherapies due to its high expression density in B cell-derived neoplasms, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin’s lymphoma (NHL) [14,97,98]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.